Please login to the form below

Not currently logged in
Email:
Password:

Norgine UK re-joins ABPI

Firm resigned its membership in 2008 in protest over lack of representation
ABPI

Norgine has re-joined UK trade body the Association of the British Pharmaceutical Industry (ABPI), nine years after denouncing its approach to pricing negotiations.

The Netherlands-based firm resigned its ABPI membership in 2008 in protest over a perceived lack of representation for smaller, specialised pharmaceutical developers, taking particular issue with talks on the PPRS.

Speaking at the time, Norgine chief operating officer Peter Martin said the company felt the ABPI's agenda had been “driven by the interests of its largest multinational members”.

This had, he added, “resulted in perverse consequences for those of us who are trying to help patients and their carers in more specialised niches, such as gastroenterology”.

Alongside gastroenterology, Norgine specialises in hepatology, oncology and pain management, and manufactures its medicines and medical devices in Hengoed, Wales, where it is the region's largest pharmaceutical manufacturing employer.

Announcing the firm's decision to return to the ABPI fold, Martin said: “The work of the ABPI is fundamental in ensuring that the interests of large and small pharmaceutical companies are well represented when leaving the EU and ultimately, to ensure that UK patients are not left behind when the rest of Europe are accessing new treatments.”

The company also has offices in Harefield, England, where it shares joint responsibility for Norgine's global operations with its headquarters in Amsterdam.

ABPI chief executive Mike Thompson said: “These are exciting and challenging times for our industry - we look forward to working with all the staff at Norgine to ensure the UK remains at the forefront of helping patients prevent and overcome diseases.

“As we plan for life outside the European Union and address the opportunities within the government's Industrial Strategy, having Norgine's support, with their heritage of adapting and responding to challenges together with their focus on innovation and partnership, comes at an opportune time.”

Article by
Rebecca Clifford

17th February 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics